New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA
Karl-Erik Andersson Institute of Regenerative Medicine, Wake Forest University School of Medicine, and Department of Urology, Wake Forest Baptist Medical Center, Winston Salem, NC, USA Abstract: In the last few years, much new information has been generated on the pathophysiology, possible therapeut...
Saved in:
Main Author: | Andersson KE (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2013-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Mirabegron in the Management of Overactive Bladder Syndrome
by: O'Kane M, et al.
Published: (2022) -
Treatment of Non-neurogenic Overactive Bladder with OnabotulinumtoxinA: Systematic Review and Meta-analysis of Prospective, Randomized, Placebo-controlled Clinical Trials
by: Raquel Martins Arruda, et al.
Published: (2018) -
Profile of mirabegron in the treatment of overactive bladder: place in therapy
by: Sharaf A, et al.
Published: (2017) -
Pharmacoeconomic feasibility of using Mirabegron in patients with overactive bladder
by: I. N. Dyakov, et al.
Published: (2021) -
Assessing Quality-of-Life of Patients Taking Mirabegron for Overactive Bladder
by: Shaw C, et al.
Published: (2023)